Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Eli Lilly and Company
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06948422CT.gov A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | — | Active Not Recruiting | — | — | — |
NCT06948435CT.gov A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | — | Active Not Recruiting | — | — | — |
NCT06952530CT.gov A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypertensive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Orforglipron (this asset) | Eli Lilly and Company | P3 | B · 57 |
| Valsartan | University of Alabama at Birmingham | P4 | BBB |
| Hydrochlorothiazide | University of Kansas Medical Center | P4 | BBB |
| Amlodipine | Jing Liu | P4 | BBB |
| Losartan | Rong Zhang | P4 | BBB |
| Trandolapril | University of Florida | P4 | BBB |
| Corpril | University of Michigan | P4 | BBB |
| Olmesartan Medoxomil | Virginia Polytechnic Institute and State University | P4 | BBB |
| Cilnidipine | Boryung Pharmaceutical Co., Ltd | P4 | BBB |
+42 more in the Hypertensive Disorder cohort
Other indications for Orforglipron
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | P3 | BB · 68 |
| Chronic Kidney Disease | — | P3 | B · 62 |
| Atherosclerotic Cardiovascular Disease | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Orforglipron in Hypertensive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/orforglipron-hypertensive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →